NCT01459601Unknown不适用
Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 10
- 主要终点
- FBS (fasting blood sugar)
研究概览
简要总结
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
排除标准
- •HbA1C>10
- •Psychiatric disorders
结局指标
主要结局
FBS (fasting blood sugar)
时间窗: 30days
次要结局
- HbA1C(30days)
研究者
Haleh Rokni Yazdi
assisstant professor
Mashhad University of Medical Sciences
相似试验
Unknown
3 期
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM PatientsDiabetesNCT03313661Sherief Abd-Elsalam60
已完成
2 期
Effect of Cabergoline on biochemical and anthropometric parameters of patients with prediabetes.Impaired Glucose Tolerance/Impaired Fasting Glucos.Impaired glucose tolerance (oral)R73.02IRCT20170608034390N6Shahid Beheshti University of Medical Sciences98
招募中
3 期
The effect of Cabergoline on blood glucose control in type 2 diabetic patientsIRCT20100314003565N9Tabriz University of Medical Sciences50
已完成
1 期
Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic ControlGlycemic ControlNCT00460499American Heart Association250
已完成
4 期
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinType II DiabetesNCT02429258AstraZeneca226